Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

Circulating tumor DNA in advanced anal cancer: a blood biomarker goes viral

(2019) Van K. Morris   CLINICAL CANCER RESEARCH

1903PMyeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma

(2019) C Borg et al.   ANNALS OF ONCOLOGY

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study

(2018) Stefano Kim et al.   LANCET ONCOLOGY

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical validity of HPV circulating tumor DNA in advanced anal carcinoma: an ancillary study to the Epitopes-HPV02 trial

(2018) Alice Bernard-Tessier et al.   CLINICAL CANCER RESEARCH

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study

(2017) Van K Morris et al.   LANCET ONCOLOGY

International trends in anal cancer incidence rates

(2016) Farhad Islami et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53

(2015) D Meulendijks et al.   BRITISH JOURNAL OF CANCER

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

(2015) Lorenzo Galluzzi et al.   CANCER CELL

High-sensitivity human papilloma virus genotyping reveals near universal positivity in anal squamous cell carcinoma: Different implications for vaccine prevention and prognosis

(2015) Ivona Baricevic et al.   EUROPEAN JOURNAL OF CANCER

Evaluation of a 36 Gy elective node irradiation dose in anal cancer

(2015) Alexis Lépinoy et al.   RADIOTHERAPY AND ONCOLOGY

Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells

(2015) Joao Paulo Oliveira-Costa et al.   Oncotarget

DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma

(2013) S. Kim et al.   ANNALS OF ONCOLOGY

Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma

(2013) S. Lyford-Pike et al.   CANCER RESEARCH

PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer

(2012) C. Badoual et al.   CANCER RESEARCH